Effect of PPV on retinal vessel oxygen saturation

Article

PPV has been a major advancement in the treatment of retinal diseases, however, little is known about its effect on oxygen metabolism in retinal vessels. In this article, Dr Sin reveals the results of his pilot study examining the effect of PPV on the oxygen saturations in retinal vessels.

The retina has a high demand for oxygen and starvation of this element in retinal vessels is considered to be an important factor in certain diseases, such as diabetic retinopathy and glaucoma.1 To examine the effect of PPV on oxygen saturation in retinal vessels a new tool, oximetry,2 was employed, explained Dr Martin Šín (Department of Ophthalmology, University Hospital Olomouc, The Czech Republic) when discussing the initial reasoning behind his recent pilot study.3 "Our head of department, Professor J. Rehak, has been researching retinal vein occlusion for many years. In 2011, he bought an automatic retinal oximetry (Oxymap, Reykjavik, Iceland) device allowing us to investigate the oxygen saturation in retinal vessels," he said.

Investigating the influence of PPV

Oximetry was performed 24 hours before PPV and then ranging between 42 and 49 days after PPV, which was either 20G or sutureless 23G. Oxygen saturation levels were examined in both retinal arteries and veins and vessel segments of first or second degree were selected. These specific segments were analysed before and after PPV to determine whether there was any change or effect of the surgery on oxygen saturation. The comparison of this data was performed using two-tailed t-test.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Related Content
© 2025 MJH Life Sciences

All rights reserved.